Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.
US-based exosome therapeutics developer Codiak Biosciences has gone public in an $82.5m initial public offering offering an exit to University of Texas System.
The company is issuing 5.5 million shares on the Nasdaq Global Market priced at $15 each, in the middle of the offering’s $14 to $16 range. It had previously filed for an IPO in May 2019, but cancelled those plans within two months.
Codiak is developing medicines to treat diseases with high unmet…
